Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Cancer Med
; 10(7): 2332-2340, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33666378
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Curcumin
/
Prostatic Neoplasms, Castration-Resistant
/
Docetaxel
/
Antineoplastic Agents
Type of study:
Clinical_trials
Aspects:
Patient_preference
Limits:
Adult
/
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer Med
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: